{
  "trial_id": "NCT03665545",
  "overall_assessment": "likely_ineligible",
  "inclusion": [],
  "exclusion": [
    {
      "criterion": "Any other vaccination given within 2 weeks before first IMA950 vaccination.",
      "label": "does_not_trigger",
      "evidence": "none"
    },
    {
      "criterion": "Diagnosis of immunodeficiency or active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a condition other than glioblastoma that requires systemic steroids (> 10mg/day prednisone or equivalent) or immunosuppressive agents.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients with evidence of history bleeding diathesis.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Pregnant or breastfeeding patients, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.",
      "label": "does_not_trigger",
      "evidence": "none"
    },
    {
      "criterion": "Has a known history of active TB (Bacillus Tuberculosis)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Hypersensitivity to pembrolizumab or any of its excipients.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient's history of anaplastic astrocytoma and current treatment regimen do not provide clear evidence for exclusion criteria. However, patient's age (45) and sex (male) are not mentioned in the trial exclusion criteria.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT03665545",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b"
  }
}